A critical function for type I interferons in cancer immunoediting

By G. Dunn, Allen T. Bruce, K. Sheehan, V. Shankaran, Ravi Uppaluri, J. Bui, Mark S. Diamond, Catherine M. Koebel, C. Arthur, J. White and 1 more. Nature Immunology, 2005

618 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/5480fed6cc88de4bc6ecfabfac85564f0dc3a2be

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity (2015, background): “The latter can act in part by dampening production of type I interferons, IL-12, and other factors that are required for priming or restimulating anti-tumor T cells and for sustaining T cell-independent anti-tumor immunity (Dunn et al., 2005; Vesely et al., 2011).”
Cancer despite immunosurveillance: immunoselection and immunosubversion (2006, background): “Interestingly, it seems that type I IFNs (that is, IFNα and IFNβ), which have an important role in immuno-surveillanc”
IDO in the Tumor Microenvironment: Inflammation, Counter-regulation and Tolerance (2016, neutral): “Moreover, IFNαβ signaling impeded growth of carcinogen-induced and transplantable tumors [75].”
Type I interferon is selectively required by dendritic cells for immune rejection of tumors (2011, neutral): “For IFN  /  receptor blockade, mice were injected i.p. with a single 2.5mg dose of IFNAR1specific MAR15A3 mAb (Sheehan et al., 2006) or GIR208 isotype control mAb as described previ ously (Dunn et al., 2005).”
Interferons, immunity and cancer immunoediting (2006, background): “This concept evolved from the observation that tumours from immunocompetent hosts and immunodeficient hosts have different immunogenic phenotype”
The Efficacy of Radiotherapy Relies Upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity (2011, positive): “More recently, it has been shown that endogenous type I IFN production plays a critical role in tumor immunoediting (12, 13).”
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells (2011, background): “Although a role for type I IFNs has been described for immunosurveillance against carcinogen-induced tumors and for rejection of transplanted tumors (Dunn et al., 2005, 2006), the source of type I IFNs and the mechanism of action of this cytokine during the priming phase of an antitumor immune…”